BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label. The FDA greenlit ...